Objective: Evaluate correlations between dyskinesia, health-related quality of life (HRQoL), activities of daily living (ADL), and pain in patients with advanced Parkinson’s disease (PD) who participated in the DYSCOVER study.
Background: While PD motor complications are associated with reduced HRQoL, it is less clear how dyskinesias specifically impact pain, ADL, and HRQoL.
Method: DYSCOVER (DYSkinesia COmparative interventional trial on Duodopa VERsus oral medication; NCT02799381) was a phase 3b, multicenter, randomized, open-label study. Patients with advanced, levodopa-responsive PD were randomized 1:1 to receive 12 weeks of levodopa-carbidopa intestinal gel or optimized medical treatment. In this post hoc analysis, combined data from both treatment groups (n=60) were analyzed for correlations between measures of dyskinesia (Unified Dyskinesia Rating Scale [UDysRS]), HRQoL (8-item Parkinson’s Disease Questionnaire [PDQ-8]), ADL (Unified Parkinson’s Disease Rating Scale part II [UPDRS II]), and pain (King’s PD Pain Scale [KPPS]). Pearson correlation coefficients were used to analyze outcomes at baseline and changes from baseline at week 12.
Results: Strong correlations were observed for improvements in UDysRS and KPPS total score; improvements in UPDRS II and KPPS total score; improvements in UPDRS II and KPPS fluctuation-related domain; and improvements in PDQ-8 and KPPS total score [Table 1]. Most other correlations were moderate, except for baseline UPDRS II with KPPS total score; baseline UPDRS II with KPPS fluctuation-related domain; improvements in UDysRS with KPPS fluctuation-related domain; and baseline UDysRS, UPDRS II, and PDQ-8 with KPPS dyskinesia item, all of which were weakly correlated. Improvements in KPPS dyskinesia item were not significantly correlated with improvements in other outcomes. With some exceptions, most correlations were significant and stronger for improvements from baseline than for corresponding baseline values. Safety results were previously reported.
Conclusion: At baseline, there were significant moderate correlations between dyskinesia and HRQoL, ADL, and pain. After treatment, there were strong correlations between improvements in dyskinesia and pain, ADL and pain, and HRQoL and pain, and moderate correlations between improvements in dyskinesia and HRQoL, and dyskinesia and ADL. Improvements in dyskinesia may be associated with improvements in pain, ADL, and HRQoL.
To cite this abstract in AMA style:
E. Freire Alvarez, P. Vanni, E. Kurca, L. Lopez Manzanares, N. Kovacs, C. Spanaki, Y. Liu, T. Gao, L. Bergmann, O. Sanchez-Solino, L. Barbato. Dyskinesia, Pain, and Quality of Life in Parkinson’s Disease: Post Hoc Analysis From the DYSCOVER Study [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/dyskinesia-pain-and-quality-of-life-in-parkinsons-disease-post-hoc-analysis-from-the-dyscover-study/. Accessed November 22, 2024.« Back to MDS Virtual Congress 2021
MDS Abstracts - https://www.mdsabstracts.org/abstract/dyskinesia-pain-and-quality-of-life-in-parkinsons-disease-post-hoc-analysis-from-the-dyscover-study/